Versigent Lifts FY26 Sales and FCF Outlook, Adds $43M Restructuring
VGNT sits 62% above its 52-week low of $26.34 on elevated volume (2.5× avg).
Summary
Versigent raised its fiscal 2026 sales and free cash flow outlook alongside Q3 results: net sales of $2.45B, up 7.2%, and adjusted EBITDA of $275M, up 10.9%. EPS fell 8.4% to $1.41, so the bottom line lagged even as the top line grew. The company also laid out a restructuring of overhead, staffing and manufacturing capacity carrying about $43M in costs over the next 12 months — a real charge against near-term earnings that the guidance raise partly offsets. Analysts trimmed their 12-month average price target to $55.44 from $55.89 while keeping a Buy rating, with 10 Buys and one Hold across 11 analysts. The guidance raise and cost plan are the actionable pieces; the PT change is noise.
At the time of this announcement, VGNT was trading at $42.80 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3B. The 52-week trading range was $26.34 to $50.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.